Paul Tudor Jones Tarsus Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 18,696 shares of TARS stock, worth $482,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,696Holding current value
$482,543% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding TARS
# of Institutions
166Shares Held
39.5MCall Options Held
190KPut Options Held
92.9K-
Rtw Investments, LP New York, NY3.27MShares$84.5 Million1.91% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.86MShares$73.9 Million3.9% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$68.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.4MShares$61.9 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$58.2 Million9.98% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $688M
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...